US Bancorp DE Has $153,000 Stake in Omnicell, Inc. (NASDAQ:OMCL)

US Bancorp DE lowered its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 61.6% during the third quarter, Holdings Channel.com reports. The firm owned 3,498 shares of the company’s stock after selling 5,612 shares during the period. US Bancorp DE’s holdings in Omnicell were worth $153,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in OMCL. Texas Permanent School Fund Corp grew its holdings in Omnicell by 1.2% during the 1st quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock worth $1,158,000 after acquiring an additional 479 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Omnicell in the first quarter valued at approximately $684,000. Inspire Investing LLC increased its holdings in shares of Omnicell by 19.2% in the first quarter. Inspire Investing LLC now owns 12,111 shares of the company’s stock valued at $354,000 after purchasing an additional 1,952 shares in the last quarter. ProShare Advisors LLC raised its position in Omnicell by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock worth $265,000 after purchasing an additional 626 shares during the last quarter. Finally, Entropy Technologies LP acquired a new position in Omnicell during the 1st quarter worth $227,000. Institutional investors own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on OMCL. Barclays lifted their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Benchmark reissued a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. JPMorgan Chase & Co. upped their target price on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Bank of America reiterated a “neutral” rating and set a $57.00 price target (up previously from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Finally, StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Friday. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $50.83.

Omnicell Trading Down 2.0 %

Omnicell stock opened at $45.67 on Friday. The firm has a market capitalization of $2.12 billion, a P/E ratio of -117.10, a PEG ratio of 46.03 and a beta of 0.81. The business has a 50-day moving average of $44.19 and a 200-day moving average of $36.70. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.